- Trials with a EudraCT protocol (182)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
182 result(s) found for: Clinical Associate.
Displaying page 1 of 10.
EudraCT Number: 2011-003313-42 | Sponsor Protocol Number: AGO-TEA | Start Date*: 2012-03-29 |
Sponsor Name:Hospital General Universitario de Alicante | ||
Full Title: Efficacy of agomelatine on sleep disturbance in Autism Spectrum Disorder (ASD) | ||
Medical condition: The treatment of sleep disorders in patients with autism spectrum disorders (ASD) | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: ES (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2011-006209-83 | Sponsor Protocol Number: 2011/198/HP | Start Date*: Information not available in EudraCT | |||||||||||
Sponsor Name:CHU - Hôpitaux de Rouen | |||||||||||||
Full Title: Evaluation of the Immune Response against Neisseria meningitidis B:14, P1-7,16 in subjects inoculated by MenBVac ® vaccine. | |||||||||||||
Medical condition: Immunogenic Study, in french children living in the region of Normandy, France, after vaccination for B:14:P1.7,16, to evaluate the longer-term persistence of antibodies against B:14P1.7,16. bacter... | |||||||||||||
|
|||||||||||||
Population Age: Children, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2011-006268-27 | Sponsor Protocol Number: 2011/199/HP | Start Date*: Information not available in EudraCT | |||||||||||
Sponsor Name:CHU - Hôpitaux de Rouen | |||||||||||||
Full Title: Evaluation of the Immune Response against Neisseria meningitidis B:14,P1-7,16 in subjects inoculated by MenBVac (R) vaccine. | |||||||||||||
Medical condition: Immunogenic Study, in french children living in the region of Normandy, France, after vaccination for B:14,P1-7,16 bacterial strain. | |||||||||||||
|
|||||||||||||
Population Age: Children, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-002849-42 | Sponsor Protocol Number: RC-P0103 | Start Date*: 2021-04-21 | |||||||||||||||||||||
Sponsor Name:GROUPEMENT DES HOPITAUX DE L'INSTITUT CATHOLIQUE DE LILLE | |||||||||||||||||||||||
Full Title: | |||||||||||||||||||||||
Medical condition: | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: FR (Trial now transitioned) | |||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2012-005450-30 | Sponsor Protocol Number: ABI-MS-P01 | Start Date*: 2014-01-08 |
Sponsor Name:Medizinische Universität Innsbruck | ||
Full Title: Anti-Biopharmaceutical Immunization: Prediction and analysis of clinical relevance to minimize the risk of immunization in multiple sclerosis patients on interferon-beta treatment | ||
Medical condition: Development of neutralising antibodies against Interferon-beta in the treatment of multiple sclerosis | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: AT (Completed) SE (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2010-019873-13 | Sponsor Protocol Number: 1200/002 | Start Date*: 2010-06-07 | |||||||||||
Sponsor Name:UCL Cliniques Universitaires Saint Luc | |||||||||||||
Full Title: Comparative study of the clinical response and cardiorespiratory endurance in early rheumatoid arthritis patients treated with Tociluzimab or Methotrexate Addendum protocol : Global gene expression... | |||||||||||||
Medical condition: early rheumatoid arthritis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-004875-61 | Sponsor Protocol Number: 15778303 | Start Date*: 2016-02-05 |
Sponsor Name:CHU TOULOUSE | ||
Full Title: Influence of apelin on insulin sensitivity in type 2 diabetic volunteers | ||
Medical condition: type 2 diabetes | ||
Disease: | ||
Population Age: Adults | Gender: Male | |
Trial protocol: FR (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2009-011044-20 | Sponsor Protocol Number: D1710C00006 | Start Date*: 2009-04-08 | |||||||||||
Sponsor Name:AstraZeneca AB | |||||||||||||
Full Title: A Single-Centre, Double-blind, Double-dummy, Randomised, Placebo Controlled, Four Period Crossover Study to Assess the Effect of Single Oral Doses of AZD5672 (600mg and 150mg) on QT/QTc Interval, C... | |||||||||||||
Medical condition: rheumatoid arthritis | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-004840-51 | Sponsor Protocol Number: EIP19-NFD-401 | Start Date*: 2019-06-26 | |||||||||||
Sponsor Name:EIP Pharma, Inc. | |||||||||||||
Full Title: A Double-Blind, Placebo-Controlled Two-Period 10-Week Treatment Within-Subject Crossover Study Of Cognitive Effects Of Neflamapimod in Early-Stage Huntington Disease (HD) | |||||||||||||
Medical condition: Early-Stage Huntington Disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2006-006380-22 | Sponsor Protocol Number: ERMM1-200601 | Start Date*: 2007-02-22 | |||||||||||
Sponsor Name:CIS bio international | |||||||||||||
Full Title: Biological dosimetry in radiation synovectomy of small finger joints with Erbium [169Er] citrate | |||||||||||||
Medical condition: Patients with rheumatoid arthritis or seronegative spondylarthropathy with at least one inflamed finger joint (MCP, PIP, DIP) referred for RSO with with Erbium [169Er]citrate | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2012-001440-22 | Sponsor Protocol Number: LIVONCO2012/001 | Start Date*: 2013-06-26 |
Sponsor Name: | ||
Full Title: A PHASE II TRIAL ON NON-SMALL-CELL LUNG CANCER STEM CELLS SENSITIVITY ASSAY (LUCAS) | ||
Medical condition: Histologically/cytologically confirmed diagnosis of metastatic NSCLC. Possibility to obtain tumor tissue form primary tumor or from an accessible metastatic site, or possibility to collect any neo... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: IT (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2015-004173-32 | Sponsor Protocol Number: 1-10-72-164-15 | Start Date*: 2015-12-18 | |||||||||||
Sponsor Name:Department of Clinical Biochemestry, Aarhus University Hospital | |||||||||||||
Full Title: Personalized medicine: Administration of TNF-alpha inhibitor treatment due to serum concentration measuring. A randomized and investigator initiated study. | |||||||||||||
Medical condition: Rheumatic diseases | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2012-003876-38 | Sponsor Protocol Number: GP13-302 | Start Date*: 2015-07-21 | |||||||||||
Sponsor Name:Hexal AG (a Sandoz company) | |||||||||||||
Full Title: A randomized, double- blind, controlled, parallel-group, multicenter study to assess the safety and immunogenicity of transitioning to GP2013 or re-treatment with Rituxan® or MabThera® in patients ... | |||||||||||||
Medical condition: Rheumatoid Arthritis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) HU (Completed) PL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2022-001315-44 | Sponsor Protocol Number: TAK-935-18-002(OV935) | Start Date*: 2022-05-24 | ||||||||||||||||||||||||||
Sponsor Name:Takeda Development Center America, Inc. | ||||||||||||||||||||||||||||
Full Title: A Multicenter, Open-label, Pilot Study of TAK-935 (OV935) in Patients With 15Q Duplication Syndrome or CDKL5 Deficiency Disorder (ARCADE Study) | ||||||||||||||||||||||||||||
Medical condition: Epileptic Encephalopathies: Dravet Syndrome, Lennox Gastaut Syndrome, CDKL5 Deficiency Disorder, and Chromosome 15 Duplication Syndrome | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | |||||||||||||||||||||||||||
Trial protocol: Outside EU/EEA | ||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2017-004872-76 | Sponsor Protocol Number: RECUT-Trial | Start Date*: 2020-05-07 | |||||||||||
Sponsor Name:Medizinische Universtitätsklinik, Kantonsspital Baselland | |||||||||||||
Full Title: Reduction of corticosteroid use in outpatient treatment of exacerbated COPD – a randomized, double-blind, non-inferiority study (The “RECUT”-Trial) | |||||||||||||
Medical condition: acute exacerbation of COPD; acute exacerbation (defined solely by clinical parameters according to the Anthonisen criteria, meaning ≥2 of the following: change of baseline dyspnea, change of cough,... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: AT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-005948-33 | Sponsor Protocol Number: CDFV890A12201 | Start Date*: 2021-07-26 | |||||||||||
Sponsor Name:Novartis Pharma AG | |||||||||||||
Full Title: An open-label, single arm phase II study of DFV890 to assess the safety, tolerability and efficacy in participants with familial cold auto-inflammatory syndrome (FCAS) | |||||||||||||
Medical condition: Familial Cold Autoinflammatory Syndrome (FCAS) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) IT (Completed) FR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-003159-44 | Sponsor Protocol Number: SOGUG-2017-A-IEC(VEJ)-1 | Start Date*: 2018-09-27 | |||||||||||
Sponsor Name:Spanish Oncology Genitourinary Group | |||||||||||||
Full Title: Phase II trial of durvalumab (Medi4736) plus tremelimumab with concurrent radiotherapy in patients with localized muscle invasive bladder cancer treated with a selective bladder preservation approach | |||||||||||||
Medical condition: Localized muscle invasive bladder cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-003008-15 | Sponsor Protocol Number: CAPRI2 | Start Date*: 2021-05-27 | |||||||||||
Sponsor Name:GRUPPO ONCOLOGICO DELL'ITALIA MERIDIONALE | |||||||||||||
Full Title: CAPRI 2 GOIM study: investigate the efficacy and safety of a biomarker-driven cetuximab-based treatment regimen over 3 treatment lines in mCRC patients with RAS/BRAF wt tumors at start of first line. | |||||||||||||
Medical condition: mCRC patients with RAS/BRAF wild type tumors at start of first line treatment | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2015-003491-69 | Sponsor Protocol Number: CACZ885DCA01 | Start Date*: 2016-04-14 | |||||||||||
Sponsor Name:Novartis Pharmaceuticals | |||||||||||||
Full Title: An Open Label Study to Assess the Safety, Tolerability and Efficacy of Canakinumab (ACZ885) in Patients Aged 4 Years or Older Diagnosed With Cryopyrin-associated Periodic Syndromes (CAPS) in Canada | |||||||||||||
Medical condition: Cryopyrin Associated Periodic Syndrome | |||||||||||||
|
|||||||||||||
Population Age: Children, Under 18, Adults | Gender: Female | ||||||||||||
Trial protocol: Outside EU/EEA | |||||||||||||
Trial results: View results |
EudraCT Number: 2009-012666-31 | Sponsor Protocol Number: OG09/8956 | Start Date*: 2009-11-11 | |||||||||||
Sponsor Name:Leeds Teaching Hospitals and University of Leeds | |||||||||||||
Full Title: The role of progesterone support and genetic polymorphisms for inflammatory cytokines on the risk of developing ovarian hyperstimulation syndrome (OHSS) in women undergoing In-Vitro fertilisation/I... | |||||||||||||
Medical condition: Ovarian Hyperstimulation syndrome | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
